CompletedPhase 2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist

Lead sponsor

Neurogastrx, Inc.

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

120

Study population

Healthy volunteers, Obesity / overweight

Eligibility highlights

•BMI 22-35•Healthy volunteers

Primary endpoints

•Duration of GI-related adverse events•Treatment-emergent AEs (any)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06500429

Org study IDNG101-202

Timeline

Milestones

Study start2024-06-24actual

Study first posted2024-07-15actual

Primary completion2024-09-04actual

Study completion2024-09-13actual

Last update posted2025-09-04actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Healthy volunteersObesity / overweight

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy adult

•Male or female

•BMI between 22 - 35 kg/m2 at screening

Exclusion criteria

•Presence or history of illness that might confound the results of the study or pose an -

•History of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen

•History or presence of Type 1 or Type 2 diabetes

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Duration of GI-related adverse events

Time frame:96 hours following GLP-1 agonist injection

descriptive

Primary/protocol endpoint

Severity of GI-related adverse events

Time frame:96 hours following GLP-1 agonist injection

Treatment-emergent AEs (any)

descriptive, event

Secondary/protocol endpoint

Number of TEAEs of GI-related adverse events

Time frame:96 hours following GLP-1 agonist injection

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.